Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells 3,236 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 3,236 shares of the company’s stock in a transaction on Monday, April 28th. The stock was sold at an average price of $30.19, for a total value of $97,694.84. Following the transaction, the insider now directly owns 159,662 shares in the company, valued at approximately $4,820,195.78. This represents a 1.99 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Soleil Boughton also recently made the following trade(s):

• On Monday, April 14th, Soleil Boughton sold 3,236 shares of Hims & Hers Health stock. The stock was sold at an average price of $28.72, for a total value of $92,937.92.
• On Monday, March 3rd, Soleil Boughton sold 4,151 shares of Hims & Hers Health stock. The shares were sold at an average price of $45.14, for a total transaction of $187,376.14.
• On Monday, March 31st, Soleil Boughton sold 3,236 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.77, for a total transaction of $89,863.72.
• On Tuesday, February 18th, Soleil Boughton sold 4,152 shares of Hims & Hers Health stock. The shares were sold at an average price of $60.69, for a total value of $251,984.88.
• On Monday, February 3rd, Soleil Boughton sold 4,153 shares of Hims & Hers Health stock. The shares were sold at an average price of $35.30, for a total value of $146,600.90.

Hims & Hers Health Trading Up 13.3 %

Hims & Hers Health stock opened at $40.98 on Friday. The company has a fifty day simple moving average of $32.21 and a 200 day simple moving average of $31.43. Hims & Hers Health, Inc. has a 1-year low of $11.20 and a 1-year high of $72.98. The company has a market cap of $9.10 billion, a P/E ratio of 93.14 and a beta of 1.65.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. On average, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analyst Upgrades and Downgrades

HIMS has been the topic of a number of analyst reports. Canaccord Genuity Group increased their price target on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a research report on Wednesday, February 19th. Bank of America raised their price objective on Hims & Hers Health from $22.00 to $26.00 and gave the stock an “underperform” rating in a research note on Tuesday. BTIG Research assumed coverage on Hims & Hers Health in a report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price target for the company. Piper Sandler lifted their price objective on Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a report on Tuesday, February 25th. Finally, TD Cowen cut Hims & Hers Health from a “buy” rating to a “hold” rating and lowered their target price for the stock from $44.00 to $30.00 in a research note on Tuesday. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $36.92.

Institutional Investors Weigh In On Hims & Hers Health

Large investors have recently made changes to their positions in the stock. Farallon Capital Management LLC lifted its stake in Hims & Hers Health by 64,338.5% in the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company’s stock valued at $202,556,000 after acquiring an additional 8,364,000 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in shares of Hims & Hers Health by 192.0% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company’s stock valued at $152,436,000 after purchasing an additional 4,145,305 shares during the period. Vanguard Group Inc. lifted its stake in Hims & Hers Health by 11.1% in the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company’s stock valued at $489,817,000 after purchasing an additional 2,020,722 shares during the last quarter. Yong Rong HK Asset Management Ltd bought a new position in Hims & Hers Health during the fourth quarter worth about $41,104,000. Finally, Renaissance Technologies LLC increased its position in Hims & Hers Health by 29.0% during the fourth quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company’s stock worth $168,079,000 after buying an additional 1,562,302 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.